ARIES - Ambrisentan in Patients With Moderate to Severe Pulmonary Arterial Hypertension (PAH)

Exclusion Criteria

• •Portopulmonary hypertension;
• •Subjects with PAH due to or associated with coronary artery disease, left heart disease, interstitial lung disease, chronic obstructive pulmonary disease, veno-occlusive disease, chronic thromboembolic disease, or sleep apnea;
• •Bosentan (Tracleer®), sildenafil (Viagra®), or chronic prostanoid therapy within 4 weeks of screening;
• •Serum ALT or AST lab value that is greater than 1.5 times the upper limit of normal;
• •Contraindication to treatment with an endothelin receptor antagonist;
• •Subject with cardiovascular, hepatic, renal, hematologic, gastrointestinal, immunologic, endocrine, metabolic, or central nervous system disease that may adversely affect the safety of the subject;
• •Participation in a clinical study involving another investigational drug within 4 weeks of screening.